{
  "index": 642,
  "prompt": "\nGiven the following scenario, first consider the actors and stakeholders involved then extrapolate and present as a timeline how the situation might evolve. \nConsider as many multiple possibilities based on possible responses which are to be represented as branches on this timeline. \n\nMake sure that the timeline generated are of **HIGH QUALITY** as defined by the following criteria\n* Plausibility: Economic, financial and political plausibility of each path on the timeline \n    * High: Events are strongly supported by current macro data, institutional knowledge, and have strong analogs in history or system models (e.g., “monetary tightening leads to recession, triggering a political backlash”)\n    * Low: Contains major violations of cause-effect logic, timing, or real-world behavior (e.g., hyperinflation causes interest rate cuts during a currency collapse)\n* Novelty: Creativity/originality in the nodes and paths, are they something you may have overlooked?\n    * High: Demonstrates expert-level creative reasoning. Identifies counterintuitive paths, rare risks, or hidden feedback loops. May challenge conventional wisdom in a grounded way (e.g., “trade war accelerates global realignment of semiconductors via Middle East sovereign wealth capital”). Could lead to edge in investment or policy thinking.\n    * Low: Timeline is linear, obvious, or closely tracks past headlines or boilerplate analysis. No creative branching or exploration.\n* Elaboration: How specific and refined are the occurrences represented by the nodes?\n    * High: Timeline reads like a mini-case study. Each node could stand alone as an actionable insight. Paths show feedback loops, strategic responses, and sector-level granularity (e.g., “Volkswagen reallocates $1.2B R&D from EVs to hybrid tech in response to rare earth prices”). Truly investment-grade thinking.\n    * Low: Nodes are generic (e.g., “market reacts”, “tensions rise”) with no detail on mechanisms, actors, or consequences. Lacks causal clarity.\n* Actionable: Can this timeline inform specific investment actions or hedging strategies?\n    * High: Timeline includes sector impacts, asset class consequences, or opportunities (e.g., “short EU auto suppliers”, “long U.S. rail freight”)\n    * Low: Insightful narrative, but no clear link to tradable instruments or positioning ideas\n\nKeep to the output format below where ascii is used to represent the timeline as a tree. \n\n[Example of Scenario]\nWASHINGTON/DETROIT, April 29 (Reuters) - U.S. President Donald Trump signed a pair of orders to soften the blow of his auto tariffs on Tuesday with a mix of credits and relief from other levies on materials, and his trade team touted its first deal with a foreign trading partner.\nThe developments helped eased some investor worries about the erratic trade policies of Trump as the president visited Michigan, a cradle of the U.S. auto industry, just days before a fresh set of 25% import taxes was set to kick in on automotive components.\n\n[Example of Output]\n{\n  \"id\": \"T0\",\n  \"title\": \"Initial Event\",\n  \"description\": \"German inflation data released at 2.2%\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"ECB maintains dovish stance\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB maintains dovish stance, keeps rates low\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"German banks increase lending\",\n          \"description\": \"German banks benefit from low rates, increase lending\"\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Euro weakens\",\n          \"description\": \"Euro weakens, boosting exports\"\n        },\n        {\n          \"id\": \"T1A1.3\",\n          \"title\": \"Moderate industrial growth\",\n          \"description\": \"German industry reports moderate growth\"\n        },\n        {\n          \"id\": \"T1A1.4\",\n          \"title\": \"Bundesbank caution\",\n          \"description\": \"Bundesbank signals caution on inflation\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Industry adapts to inflation\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Companies pass on higher costs; unions request wage hikes; consumer shifts emerge\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Markets stabilize\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Eurozone growth outlook improves; German stocks outperform\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Global growth stabilizes\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Global trade rebounds; emerging markets benefit\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"New normal\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Stable growth across EU/US; ECB remains dovish\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"ECB tightens monetary policy\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB tightens policy in response to inflation\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Euro strengthens\",\n          \"description\": \"Euro strengthens, hurting exports\"\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Industrial slowdown\",\n          \"description\": \"German industry reports slower growth\"\n        },\n        {\n          \"id\": \"T1A2.3\",\n          \"title\": \"Bundesbank warns\",\n          \"description\": \"Bundesbank warns of inflation risks\"\n        },\n        {\n          \"id\": \"T1A2.4\",\n          \"title\": \"Consumers cut back\",\n          \"description\": \"German consumers cut back on spending\",\n          \"children\": [\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Industry opposes ECB policy\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Job cuts, political backlash, delayed consumption\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"Markets unstable\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Growth outlook declines; ECB remains hawkish\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Global recession risk rises\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Trade slows; emerging markets struggle\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Global downturn\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Recession conditions persist; ECB maintains rate hikes\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n\n[Given Scenario]\nThe global immunotoxins market size was estimated at USD 142.2 million in 2023 and is projected to reach USD 344.7 million by 2034, reflecting a compound annual growth rate (CAGR) of 8.11% during the forecast period of 2024 to 2034. This growth is attributed to the rising global prevalence of various malignancies, increased research and development (R&D) activities, heightened investment and funding, the approval of new immunotoxin therapies, and an increase in collaborations and partnerships.\n\nBy product, the Diphtheria Toxin (DT) segment emerged as the highest revenue-generating segment in the global immunotoxins market in 2023, due to the proven effectiveness of DT-based immunotoxins in targeted cancer therapies. The Pseudomonas Exotoxin segment is anticipated to witness the fastest CAGR during the forecast period, driven by the success of Pseudomonas exotoxin-based therapies in clinical trials and advancements that enhance tumor-targeting capabilities while reducing immunogenicity.\n\nBy application, the therapy development segment accounted for the highest revenue in the global immunotoxins market in 2023, resulting from an increased focus on creating novel immunotoxin-based therapies. The biomedical research segment is projected to grow at the fastest CAGR during the forecast period, spurred by escalating interest in exploring immunotoxins for new therapeutic applications.\n\nBy end-user, the pharmaceutical and biotechnology companies segment represented the highest revenue-generating segment in the global immunotoxins market in 2023, attributed to robust R&D efforts, strong product pipelines, strategic partnerships, and the growing commercialization of innovative immunotoxin-based therapies. The academic and research institutes segment is expected to exhibit the fastest CAGR during the forecast period, driven by increased emphasis on fundamental research, heightened collaboration with pharmaceutical companies, access to government and private research funding, and advancements in the early-stage development of new immunotoxin therapies.\n\nNorth America is anticipated to have the highest revenue share during the forecast period owing to the presence of major pharmaceutical and biotechnology companies, advanced healthcare infrastructure, high investment in cancer research, and early adoption of innovative immunotoxin therapies. The Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of cancer, increasing healthcare expenditure, growing biotechnology and pharmaceutical sectors, expanding clinical trial activities, and improvements in healthcare infrastructure in countries such as China and India.\n\nKey players in the immunotoxins market include Amgen Inc., Eisai Co. Ltd., Genentech (Roche), AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Celltech Pharma Ltd., ImmunoGen Inc., BioNTech SE, Macrogenics Inc., Cellerant Therapeutics Inc., Iovance Biotherapeutics Inc., and Zymeworks Inc.\n[Output in JSON]\n",
  "response": "```json\n{\n  \"id\": \"T0\",\n  \"title\": \"Global Immunotoxins Market Growth Begins\",\n  \"description\": \"In 2024, the global immunotoxins market is set to expand, driven by rising prevalence of malignancies, increased R&D, and strategic investments.\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"Regulatory Environment Facilitates Growth\",\n      \"date_range\": \"2024–2026\",\n      \"description\": \"Regulatory bodies streamline approval processes for immunotoxin therapies, encouraging faster market entry.\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"Accelerated Approvals for DT-Based Therapies\",\n          \"description\": \"Agencies like FDA and EMA grant accelerated approvals for Diphtheria Toxin (DT) based immunotoxins.\",\n          \"children\": [\n            {\n              \"id\": \"T1A1.1.1\",\n              \"title\": \"Pharmaceutical Companies Expand DT Pipelines\",\n              \"description\": \"Key players such as Amgen and Genentech invest $500M in expanding DT-based therapy pipelines.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A1.1.1.1\",\n                  \"title\": \"Increased DT Therapy Availability\",\n                  \"description\": \"Market sees a 30% increase in available DT-based therapies, enhancing treatment options.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A1.1.1.1.1\",\n                      \"title\": \"Stock Performance Boost\",\n                      \"description\": \"Shares of leading pharmaceutical companies experience a 15% rise due to expanded pipelines.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T1A1.1.1.1.1.1\",\n                          \"title\": \"Investment Opportunities in Biotech ETFs\",\n                          \"description\": \"Investors consider increasing holdings in biotech-focused ETFs to capitalize on sector growth.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Pseudomonas Exotoxin Therapies Gain Traction\",\n          \"description\": \"Regulatory support leads to successful Phase III trials for Pseudomonas Exotoxin-based immunotoxins.\",\n          \"children\": [\n            {\n              \"id\": \"T1A1.2.1\",\n              \"title\": \"Strategic Partnerships Form\",\n              \"description\": \"Companies like BioNTech and Zymeworks enter partnerships to co-develop exotoxin therapies.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A1.2.1.1\",\n                  \"title\": \"Joint Ventures in Asia Pacific\",\n                  \"description\": \"Partnerships focus on expanding clinical trials and manufacturing in high-growth Asia Pacific regions.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A1.2.1.1.1\",\n                      \"title\": \"Market Share Expansion\",\n                      \"description\": \"Asia Pacific accounts for 25% of global immunotoxins sales by 2026.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T1A1.2.1.1.1.1\",\n                          \"title\": \"Local Biotech Investments Surge\",\n                          \"description\": \"Investors pour capital into Asia-based biotech firms specializing in immunotoxins.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"Regulatory Hurdles Impede Market Growth\",\n      \"date_range\": \"2024–2026\",\n      \"description\": \"Stringent regulations and extended approval timelines slow the adoption of new immunotoxin therapies.\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Increased Scrutiny on Immunogenicity\",\n          \"description\": \"Regulators demand more comprehensive data on immunogenicity of immunotoxins, delaying approvals.\",\n          \"children\": [\n            {\n              \"id\": \"T1A2.1.1\",\n              \"title\": \"R&D Investment Shifts\",\n              \"description\": \"Companies reallocate R&D funds towards reducing immunogenicity, impacting overall growth speed.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A2.1.1.1\",\n                  \"title\": \"Extended Development Timelines\",\n                  \"description\": \"Average time to market for new therapies extends by 2 years.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A2.1.1.1.1\",\n                      \"title\": \"Delayed Revenue Streams\",\n                      \"description\": \"Pharmaceutical firms experience slower revenue growth, affecting stock valuations.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T1A2.1.1.1.1.1\",\n                          \"title\": \"Investor Caution\",\n                          \"description\": \"Investors adopt a wait-and-see approach, reducing allocations to high-risk biotech stocks.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Regulatory Rejections for Novel Therapies\",\n          \"description\": \"Several new immunotoxin therapies face rejections due to unmet safety benchmarks.\",\n          \"children\": [\n            {\n              \"id\": \"T1A2.2.1\",\n              \"title\": \"Reputation Impact on Companies\",\n              \"description\": \"Companies like AbbVie and Novartis face reputational setbacks, impacting investor confidence.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A2.2.1.1\",\n                  \"title\": \"Strategic Reorientation\",\n                  \"description\": \"Firms pivot towards more established therapies, limiting focus on innovative immunotoxins.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A2.2.1.1.1\",\n                      \"title\": \"Reduced Market Diversification\",\n                      \"description\": \"Portfolio diversification decreases, increasing vulnerability to sector-specific risks.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T1A2.2.1.1.1.1\",\n                          \"title\": \"Hedging Strategies Adopted\",\n                          \"description\": \"Investors implement hedging strategies against biotech sector downturns.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A3\",\n      \"title\": \"Technological Breakthroughs Enhance Market Potential\",\n      \"date_range\": \"2025–2028\",\n      \"description\": \"Innovations in immunotoxin engineering lead to more effective and safer therapies, boosting market growth.\",\n      \"children\": [\n        {\n          \"id\": \"T1A3.1\",\n          \"title\": \"Advanced Tumor-Targeting Technologies\",\n          \"description\": \"New targeting mechanisms improve precision of immunotoxins, reducing off-target effects.\",\n          \"children\": [\n            {\n              \"id\": \"T1A3.1.1\",\n              \"title\": \"Enhanced Clinical Trial Success Rates\",\n              \"description\": \"Improved targeting leads to higher success rates in clinical trials for new therapies.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A3.1.1.1\",\n                  \"title\": \"Faster Market Approvals\",\n                  \"description\": \"Higher success rates accelerate the approval process, increasing market entry speed.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A3.1.1.1.1\",\n                      \"title\": \"Market Expansion\",\n                      \"description\": \"Global market size reaches USD 200 million by 2028, surpassing projections.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T1A3.1.1.1.1.1\",\n                          \"title\": \"New Entrants and Increased Competition\",\n                          \"description\": \"Breakthroughs attract new companies into the immunotoxins space, intensifying competition.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A3.2\",\n          \"title\": \"Reduction in Production Costs\",\n          \"description\": \"Innovations in manufacturing processes lower the cost of producing immunotoxins.\",\n          \"children\": [\n            {\n              \"id\": \"T1A3.2.1\",\n              \"title\": \"Price Competitiveness Improves\",\n              \"description\": \"Lower production costs enable more competitive pricing, increasing accessibility.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A3.2.1.1\",\n                  \"title\": \"Increased Adoption in Emerging Markets\",\n                  \"description\": \"More affordable therapies lead to higher adoption rates in price-sensitive regions like Asia Pacific.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A3.2.1.1.1\",\n                      \"title\": \"Regional Market Leaders Emerge\",\n                      \"description\": \"Companies with cost advantages dominate key emerging markets, enhancing global presence.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A4\",\n      \"title\": \"Competitive Pressures from Alternative Therapies\",\n      \"date_range\": \"2025–2030\",\n      \"description\": \"Growth of alternative cancer therapies like CAR-T and checkpoint inhibitors challenges the immunotoxins market.\",\n      \"children\": [\n        {\n          \"id\": \"T1A4.1\",\n          \"title\": \"Innovation in Alternative Therapies\",\n          \"description\": \"Breakthroughs in CAR-T and checkpoint inhibitors offer comparable or superior efficacy.\",\n          \"children\": [\n            {\n              \"id\": \"T1A4.1.1\",\n              \"title\": \"Shifts in Clinical Preferences\",\n              \"description\": \"Clinicians increasingly prefer alternative therapies due to better patient outcomes.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A4.1.1.1\",\n                  \"title\": \"Reduced Demand for Immunotoxins\",\n                  \"description\": \"Market demand shifts away from immunotoxins, slowing their growth trajectory.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A4.1.1.1.1\",\n                      \"title\": \"Strategic Alliances Formed\",\n                      \"description\": \"Immunotoxin companies form alliances with tech firms to integrate complementary therapies.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A4.2\",\n          \"title\": \"Economic Pressures Limit Healthcare Budgets\",\n          \"description\": \"Rising costs of alternative therapies strain healthcare budgets, impacting overall immunotoxins market.\",\n          \"children\": [\n            {\n              \"id\": \"T1A4.2.1\",\n              \"title\": \"Price Negotiations Intensify\",\n              \"description\": \"Healthcare providers negotiate harder on prices, squeezing immunotoxin margins.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A4.2.1.1\",\n                  \"title\": \"Focus on Cost-Effective Solutions\",\n                  \"description\": \"Companies prioritize developing cost-effective immunotoxins to maintain competitive edge.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A5\",\n      \"title\": \"Increased Strategic Collaborations and Partnerships\",\n      \"date_range\": \"2026–2028\",\n      \"description\": \"Collaborations between pharmaceutical companies, biotech firms, and academic institutions drive innovation and market expansion.\",\n      \"children\": [\n        {\n          \"id\": \"T1A5.1\",\n          \"title\": \"Public-Private Partnerships Formed\",\n          \"description\": \"Governments partner with private firms to fund immunotoxin research and development.\",\n          \"children\": [\n            {\n              \"id\": \"T1A5.1.1\",\n              \"title\": \"Enhanced R&D Capabilities\",\n              \"description\": \"Collaborative funding boosts R&D efforts, accelerating discovery of novel immunotoxins.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A5.1.1.1\",\n                  \"title\": \"Breakthrough Therapies Developed\",\n                  \"description\": \"New immunotoxins with higher efficacy and safety profiles enter the pipeline.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A5.1.1.1.1\",\n                      \"title\": \"Market Leadership Affirmed\",\n                      \"description\": \"Leading firms solidify their positions as market leaders through innovative offerings.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A5.2\",\n          \"title\": \"Academic and Industry Collaborations\",\n          \"description\": \"Joint efforts with academic institutions enhance fundamental research and therapeutic development.\",\n          \"children\": [\n            {\n              \"id\": \"T1A5.2.1\",\n              \"title\": \"Access to Cutting-Edge Research\",\n              \"description\": \"Pharmaceutical companies gain access to novel discoveries, accelerating product development.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A5.2.1.1\",\n                  \"title\": \"Pipeline Diversification\",\n                  \"description\": \"Broadening of product pipelines reduces dependency on single therapy types.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T1A5.2.1.1.1\",\n                      \"title\": \"Risk Mitigation Achieved\",\n                      \"description\": \"Diversified pipelines provide stability against market and regulatory uncertainties.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A6\",\n      \"title\": \"Market Consolidation Through Mergers and Acquisitions\",\n      \"date_range\": \"2027–2030\",\n      \"description\": \"Growing competition and the need for advanced technologies drive mergers and acquisitions in the immunotoxins market.\",\n      \"children\": [\n        {\n          \"id\": \"T1A6.1\",\n          \"title\": \"Large Pharma Acquisitions of Biotechs\",\n          \"description\": \"Major pharmaceutical companies acquire innovative biotech firms specializing in immunotoxins.\",\n          \"children\": [\n            {\n              \"id\": \"T1A6.1.1\",\n              \"title\": \"Enhanced Product Portfolios\",\n              \"description\": \"Acquisitions lead to more robust and diverse immunotoxin offerings.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A6.1.1.1\",\n                  \"title\": \"Global Market Share Expansion\",\n                  \"description\": \"Consolidated entities capture larger global market shares, influencing pricing and availability.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A6.2\",\n          \"title\": \"Strategic Alliances Between Competitors\",\n          \"description\": \"Competitors form alliances to synergize research efforts and pool resources.\",\n          \"children\": [\n            {\n              \"id\": \"T1A6.2.1\",\n              \"title\": \"Shared Technological Platforms\",\n              \"description\": \"Allied companies develop shared platforms for immunotoxin production and delivery.\",\n              \"children\": [\n                {\n                  \"id\": \"T1A6.2.1.1\",\n                  \"title\": \"Cost Efficiency Achieved\",\n                  \"description\": \"Shared platforms reduce manufacturing costs and enhance scalability.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n```",
  "processing_time": 55.428852796554565,
  "estimated_prompt_tokens": 2487,
  "response_tokens": 3351
}